US-based biotechnology firm ImmunoMet Therapeutics has started its Phase I clinical trial for IM156, a potent oxidative phosphorylation (OXPHOS) inhibitor to treat patients with solid tumours.

IM156 is an orally administered small molecule from the biguanide class, and claimed to have the potential to treat both drug-resistant cancers those with molecular signatures of sensitivity to OXPHOS inhibition.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The dose escalation trial is designed to evaluate the safety and tolerability of IM156 in these patients, while its primary endpoints are to determine the maximum therapeutic dose and the randomised Phase II study dose.

ImmunoMet chief operating officer Benjamin Cowen said: “The initiation of our Phase 1 clinical study for our lead product, IM156, is a major milestone for ImmunoMet.

“We look forward to the opportunity of providing cancer patients with a potential new treatment for resistant tumours, which is still an area of significant unmet need in oncology.”

“Treatment for resistant tumours is still an area of significant unmet need in oncology.”

A total of 18-36 patients will be enrolled in the trial at Yonsei Medical Centre (South Korea), a Sister Centre of MD Anderson Cancer Centre.

The trial’s secondary endpoints are to determine pharmacodynamics, pharmacokinetics, and preliminary efficacy in solid tumour patients.

Due to transformation to mitochondrial OXPHOS from glycolysis, resistant tumour cells are very sensitive to OXPHOS inhibition and IM156 has shown strong in-vitro and in-vivo efficacy in certain cancers, including Glioblastoma (GBM), gastric and diffuse large B cell lymphoma (DLBCL).

ImmunoMet is focused on using cellular metabolism to develop new anti-tumour and immuno-oncology therapies.